Advancing Type 2 Diabetes Care With Modern Insulins

1. Advancing Type 2 Diabetes Care With Modern Insulins

2. Goals

3. Type 2 Diabetes Is Progressive

4. Most Patients Are Not Achieving HbA1C < 7%

5. DCCT Results: HbA1c and Relative Risk of Diabetic Complicationsa,b

6. By the Time of Diagnosis, β-Cell Decline Exceeds 50%

7. Most Patients With T2D Will Eventually Need Insulin

8. Basal Insulin Therapy in T2D

9. Basal Insulin Improves Glycemic Control

10. Basal Insulin Replacement Therapy

11. Currently Available Basal Insulins

12. Time-action Profiles Illustrate Variability

13. Limitations of Current Basal Insulins

14. How Often Does Hypoglycemia Occur?

15. When Does Hypoglycemia Occur?

17. Hypoglycemia Is Associated With ECG Abnormalities

18. Cost of Hypoglycemia

19. Insulin Analogs Are Associated With Lower Rates of Hypoglycemia

20. In Search of Improved Pharmacokinetic/Pharmacodynamic Profiles

21. Why We Need Better Basal Insulins

22. Novel Basal Insulins on the Horizon

23. Desired Properties for A Basal Insulin Product Relative to Existing Therapy

26. Similar Outcomes With Flexible and Fixed Once-Daily Degludec* Dosing

28. Pegylated Lispro* vs Glargine in Adults With T2D at 12 Weeks

30. Investigational New Insulin Glargine U300 (300 U/mL, Gla-300)

31. Glargine U300

32. Benefits of Newer Basal Insulins

33. Take-home Messages

34. Abbreviations

35. Abbreviations (cont)

36. References

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)